Robotic surgery used to be fodder for science fiction movies. Not anymore. They are becoming more mainstream by the day.

Barclays analyst Matt Miksic lowered the firm’s price target on Zimmer Biomet (ZBH) to $118 from $125 and keeps an Underweight rating on the ...

This was the stock's third consecutive day of losses.

Spine and orthopedic companies made strides with new robots in 2024.

At a 90-day postoperative follow-up, the study found that patients who used GLP-1s had significantly increased rates of deep vein thrombosis (1.6% vs. 0.9%), myocardial infarctions (1.6% vs. 0.9%), ...